| 產(chǎn)品編號 | bs-22150R |
| 英文名稱 | CK14+17+42+10 Rabbit pAb |
| 中文名稱 | 細胞角蛋白14抗體 |
| 別 名 | Cytokeratin 14; CK 14; ck14; Cytokeratin14; Cytokeratin-14; Dowling Meara; ebs3; Epidermolysis bullosa simplex; k14; Keratin 14; Keratin type I cytoskeletal 14; Keratin14; Koebner; Krt 14; krt14; EBS3; EBS4; NFJ; Keratin, type I cytoskeletal 14; Cytokeratin 17; CK 17; ck17; Cytokeratin17; Cytokeratin-17; Keratin, type I cytoskeletal 17; Cytokeratin 10; CK 10; ck10; Cytokeratin10; Cytokeratin-10; Keratin, type I cytoskeletal 10; Cytokeratin 42; CK 42; ck42; Cytokeratin42; Cytokeratin-42; Keratin, type I cytoskeletal 42; K1C14_HUMAN. |
| 研究領域 | 腫瘤 細胞生物 免疫學 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 克 隆 號 | |
| 交叉反應 | Human,Mouse (predicted: Rat) |
| 產(chǎn)品應用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 52 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞核 細胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CK14+17+42+10: 411-472/472 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene encodes a member of the keratin family, the most diverse group of intermediate filaments. This gene product, a type I keratin, is usually found as a heterotetramer with two keratin 5 molecules, a type II keratin. Together they form the cytoskeleton of epithelial cells. Mutations in the genes for these keratins are associated with epidermolysis bullosa simplex. At least one pseudogene has been identified at 17p12-p11. [provided by RefSeq]. Function: The nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro. Subunit: Heterotetramer of two type I and two type II keratins. keratin-14 associates with keratin-5. Interacts with TRADD and with keratin filaments. Associates with other type I keratins. Subcellular Location: Cytoplasm. Nucleus. Note=Expressed in both as a filamentous pattern. Tissue Specificity: Detected in the basal layer, lowered within the more apically located layers specifically in the stratum spinosum, stratum granulosum but is not detected in stratum corneum. Strongly expressed in the outer root sheath of anagen follicles but not in the germinative matrix, inner root sheath or hair. Found in keratinocytes surrounding the club hair during telogen. Post-translational modifications: A disulfide bond is formed between rather than within filaments and promotes the formation of a keratin filament cage around the nucleus. DISEASE: Epidermolysis bullosa simplex, Dowling-Meara type (DM-EBS) [MIM:131760]: A severe form of intraepidermal epidermolysis bullosa characterized by generalized herpetiform blistering, milia formation, dystrophic nails, and mucous membrane involvement. Note=The disease is caused by mutations affecting the gene represented in this entry. Epidermolysis bullosa simplex, Weber-Cockayne type (WC-EBS) [MIM:131800]: A form of intraepidermal epidermolysis bullosa characterized by blistering limited to palmar and plantar areas of the skin. Note=The disease is caused by mutations affecting the gene represented in this entry. Epidermolysis bullosa simplex, Koebner type (K-EBS) [MIM:131900]: A form of intraepidermal epidermolysis bullosa characterized by generalized skin blistering. The phenotype is not fundamentally distinct from the Dowling-Meara type, although it is less severe. Note=The disease is caused by mutations affecting the gene represented in this entry. Epidermolysis bullosa simplex, autosomal recessive (AREBS) [MIM:601001]: An intraepidermal epidermolysis bullosa characterized by localized blistering on the dorsal, lateral and plantar surfaces of the feet. Note=The disease is caused by mutations affecting the gene represented in this entry. Naegeli-Franceschetti-Jadassohn syndrome (NFJS) [MIM:161000]: A rare autosomal dominant form of ectodermal dysplasia. The cardinal features are absence of dermatoglyphics (fingerprints), reticular cutaneous hyperpigmentation (starting at about the age of 2 years without a preceding inflammatory stage), palmoplantar keratoderma, hypohidrosis with diminished sweat gland function and discomfort provoked by heat, nail dystrophy, and tooth enamel defects. Note=The disease is caused by mutations affecting the gene represented in this entry. Dermatopathia pigmentosa reticularis (DPR) [MIM:125595]: A rare ectodermal dysplasia characterized by lifelong persistent reticulate hyperpigmentation, non-cicatricial alopecia, and nail dystrophy. Variable features include adermatoglyphia, hypohidrosis or hyperhidrosis, and palmoplantar hyperkeratosis. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Belongs to the intermediate filament family. SWISS: P02533 Gene ID: 3861 Database links: Entrez Gene: 3861 Human Entrez Gene: 16664 Mouse Omim: 148066 Human SwissProt: P02533 Human SwissProt: Q61781 Mouse Unigene: 654380 Human Unigene: 439898 Mouse CK14屬于酸性角蛋白。在乳腺腺體和導管肌上皮細胞、唾液腺腺泡和導管的肌上皮細胞以及鱗狀上皮的基底細胞中陽性表達。大多數(shù)鱗狀細胞癌表達陽性，并且陽性表達的頻率與其分化程度無明顯關系。主要用于鱗狀細胞癌的判斷，尤其用于低分化鱗癌判斷中。 |
| 產(chǎn)品圖片 |
Sample:
A431(Human) Cell Lysate at 30 ug
Primary: Anti-CK14+17+42+10 (bs-22150R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 52 kD
Observed band size: 52 kD
Sample:
Esophageal (Mouse) Lysate at 40 ug
Primary: Anti-CK14+17+42+10 (bs-22150R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 52 kD
Observed band size: 52 kD
Paraformaldehyde-fixed, paraffin embedded (human colon carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (CK14+17+42+10) Polyclonal Antibody, Unconjugated (bs-22150R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
